Zacks Investment Research
01 Oct 2026, 13:51 UTC · 1d ago
Verdict
Headline takes no side. We score NEOG +0.90 across three claims — strongly bullish.
+0.90strongly bullish
More positive than 96% of ticker scores this week
Scored by the NIS engine · methodology.
What the story claims
3 claims · scored −1 bearish … +1 bullish · 0 new · 3 priced in
In March 2026, Neogen agreed to sell its Genomics business to Zoetis for $160 million.
Priced inevent occurred in March 2026
So whatThe $160M cash infusion likely alters the net debt position or provides capital for the FY2027 pipeline.
More positive than 87% of claims this week
In the fourth quarter of fiscal 2026, Food Safety segment core growth reached 5.8%, the highest quarterly rate since fiscal 2023.
Continue reading
5 related stories
Top 2 movers · tap to explore
Priced inanalysis of Q4 results reported earlier
So whatThis acceleration in the central growth engine suggests a potential upward revision for FY2027 revenue estimates.
More positive than 79% of claims this week
Neogen's stock price has surged 83% year-to-date.
Priced indescribes YTD trend
So whatThe outperformance relative to the S&P 500's 11.7% rise indicates a significant expansion in the stock's valuation multiple.
More positive than 53% of claims this week
Which stocks this story touches
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
GlobeNewsWire
37m ago
−3.6%
Price is moving against the score
$12.33 vs $12.80 close before publication (Sep 30) · not market-adjusted
NEOG chart →
